Jefferies Group’s Apellis Pharmaceuticals APLS Stock Holding History

Jefferies Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,214	Closed	-$507K	–	1632
2022 Q2	$507K	Buy	11,214 +10,457	+1,381%	+$477K	﹤0.01%	990
2022 Q1	$38.5K	Buy	+757	New	+$33.4K	﹤0.01%	1419
2021 Q4	–	Sell	-165,038	Closed	-$5.44M	–	1612
2021 Q3	$5.44M	Sell	165,038 -344,091	-68%	-$19.3M	0.04%	410
2021 Q2	$32.2M	Buy	509,129 +492,996	+3,056%	+$25.4M	0.2%	72
2021 Q1	$692K	Buy	+16,133	New	+$763K	0.01%	1022
2020 Q3	–	Sell	-70,976	Closed	-$2.32K	–	1335
2020 Q2	$2.32K	Buy	70,976 +58,515	+470%	+$1.88M	0.03%	499
2020 Q1	$334K	Buy	+12,461	New	+$442K	﹤0.01%	1489
2019 Q4	–	Sell	-13,429	Closed	-$324K	–	2544
2019 Q3	$324K	Buy	+13,429	New	+$370K	﹤0.01%	2135

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Jefferies Group's APLS Position: Q3 2022 in Review

Jefferies Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 11,214 shares — an estimated $507K sold.

Jefferies Group first reported a position in APLS in Q3 2019 and held it in 8 quarters. The position peaked at $32.2M in Q2 2021. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

Jefferies Group reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Jefferies Group sold 11,214 Apellis Pharmaceuticals shares in Q3 2022, an estimated $507K.
Jefferies Group first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Jefferies Group's Apellis Pharmaceuticals position peaked at $32.2M in Q2 2021.
250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.